Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biofrontera AG (B8FK.DE)
Leverkusen, DE
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.62% | +4.15% | +4.15% | -3.09% | -6.34% | +0.00% | +0.80% | -86.29% | -95.64% | -94.85% | -99.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-59.1% Q1'26: -50.1% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-11,106.9% Q1'26: +288.3% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-87.9% Q1'26: +0.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-9.2% Q1'26: +1.3% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-10.1% Q1'26: +1.4% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-90.5% ★ Q1'26: -90.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.12× Q1'26: 10.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
41.80M
est.
|
13.19M
est: 52.30M (-74.8%)
|
71.40M
71.40M – 71.40M
+36.5% YoY
|
| EBITDA |
-6.94M
est.
|
-560.0K
est: -8.68M (+93.5%)
|
-11.85M
-11.85M – -11.85M
-36.5% YoY
|
| EBIT |
-10.65M
est.
|
-1.21M
est: -13.33M (+90.9%)
|
-18.20M
-18.20M – -18.20M
-36.5% YoY
|
| Net Income |
38.91M
est.
|
-3.97M
est: 85.61M (-104.6%)
|
140.09M
140.09M – 140.09M
+63.6% YoY
|
| SGA |
43.13M
est.
|
9.44M
est: 53.97M (-82.5%)
|
73.68M
73.68M – 73.68M
+36.5% YoY
|
| EPS |
0.61
est.
|
-0.65
est: 1.34 (-148.4%)
|
2.20
2.20 – 2.20
+63.6% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ludwig Lutter | Member of the Executive Board | 435.6K | male |
| Pilar de la Huerta | Chief Financial Officer & Member of Executive Board | 411.0K | female |
| Alexander Richardson | Head of UK Sales Team | — | male |
| Matthias Naumann | Head of Sales & Marketing - Europe | — | — |
| Montserrat Foguet | Managing Director of Biofrontera UK Ltd. | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for B8FK.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
